| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 3,151 | 3,272 | 3,324 | 3,450 | 3,710 | 3,728 | 3,742 | 3,871 | 3,625 | 3,645 | 4,366 | 4,302 | 4,033 | 4,226 | 4,694 | 5,242 | 5,234 | 5,377 | 5,539 | 5,830 | 6,108 | 5,951 | 6,432 | 9,300 | 6,071 | 5,802 | 5,987 | 6,089 | 5,844 | 6,218 | 5,731 | 6,481 | 6,514 | 6,907 | 7,339 | 7,434 | 7,628 | 7,679 | 7,783 | 8,052 |
| Expenses | 2,506 | 2,574 | 2,586 | 2,688 | 2,885 | 2,878 | 2,847 | 3,011 | 2,920 | 2,845 | 3,319 | 3,311 | 3,261 | 3,539 | 3,792 | 4,208 | 4,271 | 4,311 | 4,473 | 4,701 | 4,862 | 4,679 | 5,071 | 5,011 | 4,735 | 4,502 | 4,766 | 4,993 | 5,002 | 5,303 | 4,950 | 5,453 | 5,477 | 5,772 | 5,846 | 5,753 | 6,042 | 5,949 | 6,230 | 6,401 |
| EBITDA | 645 | 698 | 738 | 762 | 825 | 851 | 895 | 860 | 704 | 800 | 1,047 | 992 | 772 | 687 | 902 | 1,033 | 963 | 1,066 | 1,066 | 1,130 | 1,247 | 1,271 | 1,361 | 4,290 | 1,335 | 1,300 | 1,220 | 1,096 | 842 | 914 | 781 | 1,027 | 1,037 | 1,135 | 1,493 | 1,681 | 1,585 | 1,730 | 1,553 | 1,652 |
| Operating Profit % | 20 % | 21 % | 22 % | 22 % | 21 % | 22 % | 23 % | 22 % | 18 % | 21 % | 24 % | 22 % | 18 % | 15 % | 19 % | 19 % | 18 % | 20 % | 19 % | 19 % | 20 % | 20 % | 20 % | 21 % | 21 % | 21 % | 19 % | 17 % | 14 % | 14 % | 13 % | 15 % | 14 % | 15 % | 18 % | 21 % | 19 % | 20 % | 19 % | 19 % |
| Depreciation | 85 | 89 | 93 | 99 | 111 | 106 | 110 | 111 | 100 | 131 | 132 | 138 | 157 | 155 | 164 | 163 | 187 | 241 | 243 | 250 | 232 | 256 | 257 | 277 | 266 | 280 | 294 | 299 | 254 | 280 | 298 | 321 | 346 | 327 | 418 | 423 | 354 | 404 | 382 | 419 |
| Interest | 21 | 31 | 68 | 9 | 25 | 21 | 18 | 14 | 14 | 17 | 17 | 19 | 25 | 30 | 35 | 48 | 50 | 50 | 41 | 37 | 32 | 21 | 16 | 20 | 18 | 13 | 10 | 16 | 9 | 15 | 25 | 45 | 56 | 57 | 68 | 76 | 89 | 111 | 113 | 119 |
| Profit Before Tax | 557 | 634 | 631 | 717 | 761 | 786 | 830 | 796 | 649 | 709 | 979 | 902 | 651 | 571 | 787 | 917 | 816 | 863 | 864 | 938 | 1,078 | 1,084 | 1,193 | 4,005 | 1,061 | 1,018 | 968 | 794 | 594 | 679 | 523 | 680 | 730 | 812 | 1,076 | 1,262 | 1,230 | 1,324 | 1,208 | 1,200 |
| Tax | 153 | 162 | 178 | 173 | 206 | 201 | 224 | 218 | 117 | 191 | 198 | 307 | 122 | 116 | 175 | 205 | 231 | 228 | 224 | 233 | 229 | 301 | 386 | 1,058 | 260 | 248 | 271 | 190 | 18 | 159 | 113 | 189 | 224 | 242 | 324 | 323 | 323 | 406 | 391 | 354 |
| Net Profit | 403 | 472 | 453 | 545 | 555 | 585 | 606 | 579 | 532 | 518 | 781 | 595 | 529 | 456 | 611 | 712 | 585 | 636 | 640 | 705 | 849 | 783 | 807 | 2,948 | 801 | 770 | 697 | 604 | 576 | 520 | 410 | 491 | 506 | 570 | 752 | 940 | 907 | 918 | 817 | 846 |
| EPS in ₹ | 13.84 | 16.18 | 7.77 | 9.32 | 9.49 | 9.99 | 10.41 | 9.88 | 9.10 | 8.85 | 13.33 | 10.16 | 9.02 | 7.78 | 10.44 | 12.15 | 9.99 | 10.85 | 10.92 | 12.04 | 14.50 | 13.32 | 13.78 | 50.31 | 13.67 | 13.14 | 11.89 | 10.32 | 9.84 | 8.88 | 6.99 | 8.38 | 8.64 | 9.74 | 12.83 | 16.04 | 15.51 | 15.69 | 14.00 | 14.56 |
Aurobindo Pharma
1,229.80
+29.45
(2.45%)
Market Cap
71,426.98 Cr
EPS
54.16
PE Ratio
19.77
Dividend Yield
0.37 %
Industry
Healthcare52 Week High
1,592.00
52 Week Low
995.30
PB Ratio
2.28
Debt to Equity
0.21
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from25 analysts
Company News
View All News
Aurobindo Pharma: Capacity Expansion and New Drugs to Offset Challenges4 days ago
Aurobindo Pharma faces short-term challenges including slow US approvals and upcoming patent expiry of Revlimid. The company is expanding capacity in China and the US, investing in new drug lines including penicillin G, respiratory, and biosimilars to offset potential revenue drops. Q3 FY2025 saw record revenue of ₹7,979 crore, but net profit declined 10% year-on-year.
Aurobindo Pharma Unit Receives VAI Classification in Inspection Report4 days ago
A unit of Aurobindo Pharma has received an inspection report that classifies the facility as 'Voluntary Action Indicated' (VAI). This classification suggests that while some objectionable conditions were found during the inspection, they are not significant enough to warrant regulatory or enforcement action. The company will likely need to address these issues voluntarily.
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,807.00 | 4,33,559.83 | 36.29 | 49,887.20 | 12.06 | 9,648 | 13.77 | 66.31 | |
| 5,847.10 | 1,55,222.13 | 74.44 | 8,184.00 | 0.89 | 1,600 | 64.53 | 54.14 | |
| 1,523.30 | 1,23,023.85 | 24.66 | 26,520.70 | 14.17 | 4,155 | 47.38 | 64.72 | |
| 3,242.60 | 1,09,744.32 | 58.60 | 10,785.70 | 11.59 | 1,656 | 13.54 | 61.48 | |
| 1,197.95 | 99,958.25 | 18.63 | 28,905.40 | 12.36 | 5,578 | 1.69 | 59.70 | |
| 2,127.45 | 97,053.75 | 33.67 | 20,141.50 | 19.94 | 1,936 | 38.82 | 62.32 | |
| 2,345.00 | 96,746.94 | 48.83 | 10,615.60 | 19.57 | 1,942 | -16.38 | 57.94 | |
| 939.50 | 94,535.68 | 20.38 | 19,831.50 | 13.82 | 3,831 | 29.92 | 52.97 | |
| 1,229.80 | 71,426.98 | 19.77 | 29,559.20 | 17.55 | 3,169 | -10.04 | 63.52 | |
| 30,618.80 | 65,062.81 | 48.19 | 6,097.20 | 10.80 | 1,201 | 16.01 | 54.89 |
Growth Rate
Revenue Growth
17.55 %
Net Income Growth
64.39 %
Cash Flow Change
2.00 %
ROE
47.91 %
ROCE
46.65 %
EBITDA Margin (Avg.)
35.82 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 12,915 | 15,920 | 16,249 | 21,101 | 26,454 | 28,928 | 33,854 | 33,922 | 39,890 | 45,072 |
| Fixed Assets | 3,706 | 4,180 | 4,834 | 6,521 | 8,475 | 9,397 | 9,374 | 10,532 | 11,024 | 14,493 |
| Current Assets | 8,299 | 10,294 | 9,206 | 12,178 | 15,332 | 16,413 | 19,824 | 18,123 | 21,460 | 23,772 |
| Capital Work in Progress | 420 | 848 | 1,458 | 1,583 | 1,669 | 1,986 | 3,062 | 3,747 | 5,390 | 3,869 |
| Investments | 20 | 123 | 246 | 312 | 360 | 555 | 591 | 997 | 543 | 372 |
| Other Assets | 8,770 | 10,769 | 9,712 | 12,686 | 15,951 | 16,991 | 20,828 | 18,645 | 22,934 | 26,338 |
| Total Liabilities | 12,915 | 15,920 | 16,249 | 21,101 | 26,454 | 28,928 | 33,854 | 33,922 | 39,890 | 45,072 |
| Current Liabilities | 6,136 | 7,840 | 6,606 | 8,666 | 12,021 | 11,385 | 10,665 | 8,156 | 11,494 | 12,199 |
| Non Current Liabilities | 1,596 | 790 | 270 | 753 | 541 | 718 | 1,260 | 1,192 | 1,544 | 3,022 |
| Total Equity | 5,182 | 7,290 | 9,374 | 11,682 | 13,892 | 16,825 | 21,929 | 24,574 | 26,852 | 29,851 |
| Reserve & Surplus | 5,127 | 7,229 | 9,313 | 11,622 | 13,832 | 16,766 | 21,871 | 24,517 | 26,781 | 29,784 |
| Share Capital | 29 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 | 59 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 313 | 340 | -424 | 892 | 666 | 871 | 2,561 | -1,164 | 230 | -1,007 |
| Investing Activities | -1,017 | -1,446 | -1,787 | -1,927 | -2,904 | -1,563 | 597 | -3,211 | -3,971 | -4,242 |
| Operating Activities | 1,237 | 1,420 | 3,279 | 1,955 | 1,651 | 4,381 | 3,329 | 5,017 | 2,387 | 2,435 |
| Financing Activities | 93 | 365 | -1,915 | 864 | 1,919 | -1,947 | -1,365 | -2,969 | 1,814 | 800 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 51.94 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.83 % | 51.80 % | 51.82 % | 51.82 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 18.02 % | 16.73 % | 16.59 % | 16.29 % |
| DIIs | 10.99 % | 12.72 % | 13.82 % | 15.11 % | 15.83 % | 15.58 % | 16.23 % | 14.89 % | 15.08 % | 15.73 % | 17.94 % | 20.23 % | 23.28 % | 24.77 % | 25.13 % | 25.20 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 8.71 % | 8.54 % | 9.60 % | 8.99 % | 8.37 % | 8.80 % | 8.65 % | 9.42 % | 8.54 % | 7.01 % | 6.15 % | 5.64 % | 5.52 % | 5.47 % | 5.33 % | 5.52 % |
| Others | 28.36 % | 26.91 % | 24.74 % | 24.07 % | 23.97 % | 23.79 % | 23.29 % | 23.85 % | 24.54 % | 25.42 % | 24.07 % | 22.29 % | 1.36 % | 1.23 % | 1.13 % | 1.17 % |
| No of Share Holders | 2,32,634 | 2,43,315 | 3,29,940 | 3,41,568 | 3,38,639 | 3,59,684 | 3,58,459 | 3,69,828 | 3,43,617 | 2,93,214 | 2,59,638 | 2,41,944 | 2,44,575 | 2,38,622 | 2,48,488 | 2,57,962 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.2 | 2.5 | 2.5 | 3 | 4 | 9 | 7.5 | 4.5 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.57 | 0.32 | 0.61 | 0.34 | 0.6 | 1.77 | 0.69 | 0.37 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Allotment Of Compulsory Convertible Preference Shares To Dr. Satakarni Makkapati By Curateq Biologics Private Limited A Wholly Owned Subsidiary Of The Company.
Classification Of US FDA Inspection At Unit V Of Apitoria Pharma Private Limited A Wholly Owned Subsidiary Of The Company - Reg.
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Termination Of License Agreement With Hilleman Laboratories Singapore Pte Limited By Auro Vaccines Private Limited
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Announcement under Regulation 30 (LODR)-Updates on Acquisition
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Classification Of US FDA Inspection At One Of The Warehouses Of Aurobindo Pharma USA Inc. A 100% Subsidiary Of The Company.
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Completion Of US FDA Pre-Approval Inspection (PAI) At Eugia Steriles Private Limited A 100% Stepdown Subsidiary Of The Company
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Newspaper Publication
Curateq Biologics Received Marketing Authorisation For Zefylti® A Filgrastim Biosimilar
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Change in Directorate
Announcement under Regulation 30 (LODR)-Acquisition
Announcement under Regulation 30 (LODR)-Investor Presentation
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Acquisition
Unaudited Financial Results For The Quarter And Nine Months Period Ended December 31 2024
Board Meeting Outcome for Outcome Of The Board Meeting Held On February 6 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Press Release - Curateq Biologics S.R.O Receives Positive Opinion From CHMP / EMA For Dyrupeg
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Unit 2 Of Apitoria Pharma Pvt. Ltd. Received EIR From US FDA With VAI Classification
Board Meeting Intimation for Intimation Of Board Meeting
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Warning Letter Received From NSE With Regard To Corporate Announcements Submitted In Letter Head Of The Company Where-In PAN Of The Company Was Mentioned
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Completion Of US FDA Inspection At Unit V Of Apitoria Pharma Private Limited, A Wholly Owned Subsidiary Of The Company
The Company Has Received An Order From The Additional Commissioner (ST), Appellate Authority, Vijayawada, Andhra Pradesh, Passed Under Relevant Provisions Of The Central Goods And Services Tax Act, 2017 And APGST Act, 2017
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Cessation
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Clarification On The News Appeared In The Media On Kakinada Seaport & Kakinada SEZ
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Collaboration And License Agreement Entered Into Between A Global Pharma Major And Aurobindo Pharma USA Inc., A Wholly Owned Subsidiary
Technical Indicators
RSI(14)
Neutral 63.52
ATR(14)
Less Volatile 34.20
STOCH(9,6)
Overbought 90.58
STOCH RSI(14)
Overbought 100.00
MACD(12,26)
Bullish 15.13
ADX(14)
Weak Trend 20.84
UO(9)
Bearish 68.88
ROC(12)
Uptrend And Accelerating 14.13
WillR(14)
Overbought -2.51
About Aurobindo Pharma
Aurobindo Pharma Limited (APL) is an Indian pharmaceutical company founded in 1986. It manufactures and markets active pharmaceutical ingredients, generic formulations, and branded pharmaceuticals globally. APL specializes in various therapeutic areas including antibiotics, antiretrovirals, cardiovascular, central nervous system, and gastroenterological products. The company operates 24 manufacturing plants worldwide and has 9 R&D facilities. APL has filed numerous Drug Master Files and Abbreviated New Drug Applications in various countries. The company has expanded through acquisitions and joint ventures in multiple countries, including the UK, Italy, and Portugal. APL has also entered the biosimilars and vaccines markets. The company serves over 150 countries and is among the top 5 manufacturers of semi-synthetic penicillins globally.
Website
Chairperson NameM R Kumar
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
